BB3008

BB3008 is a highly selective, potent small molecule inhibitor of hematopoietic progenitor kinase 1 (HPK1), also known as MAP4K1. HPK1 is a serine/threonine kinase primarily expressed in immune cells such as T cells, B cells, dendritic cells, and macrophages. It acts as a key negative feedback regulator of the T cell receptor (TCR) signaling pathway and functions as an intracellular immune checkpoint by inhibiting the proliferation and function of T and B cells, as well as antigen presentation by dendritic cells. Inhibition of HPK1 can restore immune function within the tumor microenvironment and enhance T cell-mediated anti-tumor responses. BB3008 was developed to overcome immunosuppression in the tumor microenvironment for patients with advanced solid tumors. Preclinical studies demonstrated that BB3008 activates T cell activity in vitro, inhibits tumor growth both alone and in combination with PD-1 inhibitors, has favorable pharmacokinetics, and shows controllable safety profiles without observed immune-related adverse effects in animal models. The drug is currently being evaluated in Phase 1 clinical trials for advanced solid tumors[2][3][5][7].